UCSF is rolling out an aggressive new play in the fight against Alzheimer’s, launching a nationwide clinical trial that pairs an anti-amyloid drug with an experimental tau therapy to see if a one-two punch can slow or prevent memory loss better than a single medication. The study screened its first potential participant last week, just as enrollment opens at more than 70 sites across the country. Investigators plan to recruit roughly 800 to 900 adults who are biomarker-positive but show no symptoms or only the earliest hints of cognitive change.
The study, called the Alzheimer’s Tau Platform, uses a shared master protocol that randomly assigns participants to one of three groups: donanemab (an anti-amyloid therapy) alone, an experimental tau-directed therapy alone, or a combination of both drugs. It is built so that new tau regimens can be swapped in over time, according to UCSF. The platform model lets researchers test multiple investigational products under one umbrella while directly comparing active amyloid, active tau, and combination strategies. UCSF lists Adam Boxer as a lead investigator and Paul S. Aisen among the study sponsors.
As reported by the San Francisco Chronicle, Boxer compared the approach to oncology, saying he likes to give the analogy of cancer when describing why a combination strategy might work. He told the paper the field has recently shifted toward therapies that aim to change the underlying biology of Alzheimer’s rather than just ease symptoms. The Chronicle also noted that scientists hope to enroll about 825 people at more than 70 U.S. study centers as screening ramps up.
How the trial works
Eligibility is limited to people ages 50 to 80 who are either cognitively unimpaired or have only very mild symptoms. Screening starts with blood biomarker tests for amyloid and tau, followed by confirmatory PET and MRI brain scans, according to UCSF. The protocol calls for an initial six-month period in which participants receive donanemab or placebo, followed by roughly 24 months of tau therapy either alone or in combination with donanemab. Over about 30 months, participants cycle through regular cognitive testing and imaging visits.
The platform will launch using the active immunotherapy AADVac1 as its first tau regimen, and the design allows additional tau candidates to be added later without having to build entirely new trials from scratch.
Why researchers think a two-drug approach could help
Many Alzheimer’s researchers argue that amyloid and tau likely work together to drive the most damaging brain changes, so hitting both proteins at once might blunt the disease process more effectively than a single drug. Tara Tracy of the Buck Institute told the San Francisco Chronicle that combining amyloid- and tau-directed approaches is a “transformative way of thinking,” even as she cautioned that dual therapy still might not be enough on its own.
New tau data gives researchers a reason to try
Momentum for combination trials picked up after companies reported encouraging early results from tau-targeting drugs. In May 2026, Biogen announced topline Phase 2 results for an investigational tau antisense oligonucleotide (ASO), reporting reductions in tau pathology along with signals of slowed clinical decline. The company said it will share additional data during the Biogen presentations at the Alzheimer’s Association International Conference in London. Biogen and related groups are expected to present more findings there this week, with AAIC scheduled for July 12 to 15 in London.
Risks and monitoring
Anti-amyloid monoclonal antibodies can cause amyloid-related imaging abnormalities, or ARIA, which involve brain swelling or small bleeds that show up on MRI and occasionally cause symptoms. That risk means heavy-duty safety monitoring is baked into trials like this one. Donanemab’s prescribing information includes boxed warnings about ARIA and recommends imaging-based monitoring, as outlined in the drug label on DailyMed. Recent practice guidance also details imaging and monitoring recommendations for ARIA in patients receiving anti-amyloid therapies, according to NCBI.
How to learn more
People interested in screening or enrollment can find study details and contact information on the trial registry entry at ClinicalTrials.gov (NCT06957418). Because of its platform design, the Alzheimer’s Tau Platform can plug in new tau candidates over time, which investigators say should speed up testing of multiple combination strategies without launching a separate, years-long trial for each drug.
The Alzheimer’s Tau Platform is part of a broader shift toward biology-driven, platform-style studies that aim to move promising candidates through testing more quickly. Researchers and advocates will be watching data coming out of AAIC this week for early signals on how tau-directed drugs might eventually slot into these kinds of combination approaches.
